Bridgeway Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Bridgeway Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,912	Closed	-$94.4K	–	1428
2023 Q3	$94.4K	Hold	3,912	–	–	﹤0.01%	1239
2023 Q2	$95.3K	Hold	3,912	–	–	﹤0.01%	1262
2023 Q1	$93.4K	Hold	3,912	–	–	﹤0.01%	1250
2022 Q4	$111K	Hold	3,912	–	–	﹤0.01%	1202
2022 Q3	$97K	Hold	3,912	–	–	﹤0.01%	1273
2022 Q2	$117K	Buy	3,912 +2,083	+114%	+$58.9K	﹤0.01%	1202
2022 Q1	$50K	Buy	+1,829	New	+$45.3K	﹤0.01%	1289
2014 Q4	–	Sell	-79	Closed	-$150K	–	1523
2014 Q3	$150K	Hold	79	–	–	﹤0.01%	1375
2014 Q2	$175K	Hold	79	–	–	﹤0.01%	1350
2014 Q1	$223K	Hold	79	–	–	0.01%	1300
2013 Q4	$202K	Buy	+79	New	+$182K	0.01%	1294

Other funds holding ORKA

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bridgeway Capital Management's ORKA Position: Q4 2023 in Review

Bridgeway Capital Management sold out of Oruka Therapeutics (ORKA) in Q4 2023, closing a stake of 3,912 shares — an estimated $94.4K sold.

Bridgeway Capital Management first reported a position in ORKA in Q4 2013 and held it in 11 quarters. The position peaked at $223K in Q1 2014. 25 funds tracked by Wall St. Rank hold ORKA as of Q4 2023.

Bridgeway Capital Management reported no remaining Oruka Therapeutics position as of Q4 2023 after selling out during the quarter.
Bridgeway Capital Management sold 3,912 Oruka Therapeutics shares in Q4 2023, an estimated $94.4K.
Bridgeway Capital Management first reported a position in Oruka Therapeutics in Q4 2013 and held it in 11 quarters.
Bridgeway Capital Management's Oruka Therapeutics position peaked at $223K in Q1 2014.
25 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2023.

Based on Bridgeway Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.